Utility of compression immediately after venous closure: Does it matter?

Compression stockings ablation chronic venous disease sclerotherapy thrombosis ulcer varicose veins venous closure venous insufficiency

Journal

Phlebology
ISSN: 1758-1125
Titre abrégé: Phlebology
Pays: England
ID NLM: 9012921

Informations de publication

Date de publication:
Dec 2021
Historique:
pubmed: 3 7 2021
medline: 15 12 2021
entrez: 2 7 2021
Statut: ppublish

Résumé

Leg compression after venous closures for 24-48 hours or longer is commonplace and controversial. The goal of our study was to evaluate compression immediately post-venous closures and its associated costs. Records were retrospectively reviewed after consecutive therapies of sclerotherapy, mechanochemical ablation (MOCA) & radiofrequency ablation (RFA) from 1 clinic with 2 cohorts: 7/2/13-10/15/15 were immediately ACE-wrapped for 3-5 days (AW, N = 52) and 10/20/15-1/5/16 were non ACE-wrapped (NAW, N = 49). All procedures were performed in an outpatient office setting of one surgeon (P.L.). Follow-up was within 1 week and 3 months with ultrasounds. Financial data of ACE wraps and ABD pads were assessed. Closures consisted of consecutive therapies of sclerotherapy (4 patients); MOCA (44 patients) and RFA (53 patients). No statistical difference existed in age (p = 0.61), sex (p = 0.2063); race (0.3689), CAD (p = 0.1442), ESRD (p = 0.2914), diabetes mellitus (p = 0.8943), hypertension (p = 0.681), COPD (p = 0.38), or smoking (p = 0.3628). NAW group had higher rate of hyperlipidemia (p = 0.0225), obesity (p = 0.0283), MOCA and sclerotherapy (p = 0.0005). No difference existed in pain (p = 0.8897); wound complications were too small to perform analysis; and swelling was greater in AW group compared to NAW group (p = 0.0132, OR 3.3951, CI 1.269; 9.0834). Closure rates were 98% and 100% in AW and NAW groups, respectively. NAW were only a total cost savings of $1.58 per leg per procedure. AW for compression after vein closures confers no benefit in postoperative period with no effect on closure rates; may be associated with increased swelling, discomfort, and wound complications while increasing unnecessary and negligible monetary costs. Larger sample size is needed to validate these conclusions.

Sections du résumé

BACKGROUND BACKGROUND
Leg compression after venous closures for 24-48 hours or longer is commonplace and controversial.
OBJECTIVE OBJECTIVE
The goal of our study was to evaluate compression immediately post-venous closures and its associated costs.
METHODS METHODS
Records were retrospectively reviewed after consecutive therapies of sclerotherapy, mechanochemical ablation (MOCA) & radiofrequency ablation (RFA) from 1 clinic with 2 cohorts: 7/2/13-10/15/15 were immediately ACE-wrapped for 3-5 days (AW, N = 52) and 10/20/15-1/5/16 were non ACE-wrapped (NAW, N = 49). All procedures were performed in an outpatient office setting of one surgeon (P.L.). Follow-up was within 1 week and 3 months with ultrasounds. Financial data of ACE wraps and ABD pads were assessed.
RESULTS RESULTS
Closures consisted of consecutive therapies of sclerotherapy (4 patients); MOCA (44 patients) and RFA (53 patients). No statistical difference existed in age (p = 0.61), sex (p = 0.2063); race (0.3689), CAD (p = 0.1442), ESRD (p = 0.2914), diabetes mellitus (p = 0.8943), hypertension (p = 0.681), COPD (p = 0.38), or smoking (p = 0.3628). NAW group had higher rate of hyperlipidemia (p = 0.0225), obesity (p = 0.0283), MOCA and sclerotherapy (p = 0.0005). No difference existed in pain (p = 0.8897); wound complications were too small to perform analysis; and swelling was greater in AW group compared to NAW group (p = 0.0132, OR 3.3951, CI 1.269; 9.0834). Closure rates were 98% and 100% in AW and NAW groups, respectively. NAW were only a total cost savings of $1.58 per leg per procedure.
CONCLUSION CONCLUSIONS
AW for compression after vein closures confers no benefit in postoperative period with no effect on closure rates; may be associated with increased swelling, discomfort, and wound complications while increasing unnecessary and negligible monetary costs. Larger sample size is needed to validate these conclusions.

Identifiants

pubmed: 34212789
doi: 10.1177/02683555211028533
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

841-847

Auteurs

Paul Lajos (P)

Division of Vascular Surgery, University of Pittsburgh Medical Center Hamot, Erie, PA, USA.

Scott Safir (S)

Division of Vascular Surgery, the Mount Sinai Hospital, New York, NY, USA.

Jonathan Weber (J)

Departments of Research and Cardiac Imaging, St Francis Hospital, Roslyn, NY, USA.

Ronald Bangiyev (R)

Division of Vascular Surgery, the Mount Sinai Hospital, New York, NY, USA.

Peter Faries (P)

Division of Vascular Surgery, the Mount Sinai Hospital, New York, NY, USA.

Windsor Ting (W)

Division of Vascular Surgery, the Mount Sinai Hospital, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH